Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia

NCT06813157

Status	RECRUITING
Phase	Not Applicable
Sponsor	Guangzhou Bio-gene Technology Co., Ltd
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (8)

- The subjects voluntarily signed the informed consent form;
- The age is from 4 to 75 years old (including the critical value), male or female;
- Patients clinically diagnosed as ITP (meeting the diagnostic criteria of the Chinese guidelines for the diagnosis and treatment of Primary immune Thrombocytopenia in Adults (2020 Edition)) had persistent thrombocytopenia for more than 3 months, but were ineffective to first-line drugs, second-line drugs for platelet production and rituximab, or ineffective to splenectomy / recurrence after operation.
- Patients who received other maintenance regimens (including but not limited to corticosteroids, azathioprine, danazol or mycophenolate mofetil), but the stable dose had been maintained for at least 4 weeks, and the dose should remain unchanged during the trial period;
- During screening, the liver and kidney function of the subjects met the following criteria: alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) d 3 times of the upper limit of the normal value; total bilirubin d 1.5 times of the upper limit of the normal value; creatinine d 1.5 times of the upper limit of the normal value or creatinine clearance rate \& gt; 75ml / min;

... and 3 more (see full listing online)

Exclusion (15)

- Have a history of severe allergic diseases or are allergic to research drugs;
- There may be a history of angina pectoris, myocardial infarction, heart failure, severe arrhythmia, etc.
- Combined use of anticoagulants or antiplatelet drugs;
- In the first study, he was treated with gamma globulin within 2 weeks before medication.
- The first study received rituximab within 24 weeks before treatment;

... and 10 more (see full listing online)

Locations (1 total)

Dongguan Taixin Hospital, Guangdong, Guangdong, China